Fuso Pharmaceutical Industries,Ltd. [4538.T]
TOKYO, Mar 31 (Pulse News Wire) – Fuso Pharmaceutical Industries,ltd. (4538.T) announced today that its board of directors approved a syndicated loan agreement led by Sumitomo Mitsui Banking Corporation.
The loan, aimed at funding the construction of a new facility within the Okayama plant premises, is part of the company's strategic plan to enhance its production capacity and consolidate operations at the Daiko factory. The syndicated loan, structured as a committed term loan, involves a total amount of ¥13.40 billion. It includes guarantees and other related schemes.
The contract was signed and will run until September 30, 2026 through February 15, 2029. Participating banks include Sumitomo Mitsui Banking Corporation, Sumitomo Mitsui Trust Bank, Resona Bank, Hokuriku Bank, Mitsubishi UFJ Bank, Chugoku Bank, Jozen Bank, and Mizuho Bank. This financing decision aligns with Fuso Pharmaceutical’s mid-term business strategy, “FUSO Vision 2030 Next Stage,” which targets increasing the domestic share of dialysis agents to 55% by fiscal year 2030.
The new manufacturing line will bolster the company's supply stability and support its growth objectives.
🟢 Confidence: High AI-translated content.